The present invention provides compositions and methods for treating a disease involving inappropriate or excessive cell proliferation or for treating an inflammatory condition or an autoimmune disease by inhibiting MYC activity in cells such as MYC-dependent cancer cells.

Two vIRF4 (Kaposi's-sarcoma-associated-herpesvirus vIRF4) peptides, vif1, corresponding to aa202-216 of vIRF4, and vif2, corresponding to aa220-236 of vIRF4, are potent and selective HAUSP antagonists. The vif1 and vif2 peptides robustly suppress HAUSP DUB enzymatic activity, ultimately leading to p53-mediated anti-cancer activity. The vif1 and vif2 peptides, along with their homologues, are useful in treating ALL.

The present invention relates to a peptide derived from Kaposi's sarcoma-associated herpesvirus (KSHV) vIRF3 and a use thereof. According to the present invention, the KSHV vIRF3-derived peptide inhibits the activity of PKM2, reduces the size and volume of tumors, and significantly suppresses the migration and invasion of cancer cells. Therefore, it can be advantageously utilized for the prevention, alleviation, or treatment of cancer or for inhibiting metastasis of cancer cells.

The present invention provides compositions and methods for treating a disease involving inappropriate or excessive proliferation of cells expressing CHD4.

The present invention provides compositions and methods for treating a disease involving inappropriate or excessive cell proliferation or for treating an inflammatory condition or an autoimmune disease by inhibiting MYC activity in cells such as MYC-dependent cancer cells.